Basic Information
Vaniqa
Regulatory Information
EMEA/H/C/000325
Authorised
March 19, 2001
24
November 27, 2024
Company Information
Spain
Ronda General Mitre, 151 ES-08022 Barcelona
Almirall, LLC
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of facial hirsutism in women.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Vaniqa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vaniqa.